STOCK TITAN

Alimera Sciences to Present at the Zooming with LD Micro Virtual Conference on April 15, 2021

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

ATLANTA, April 09, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, today announced that Rick Eiswirth, President and Chief Executive Officer, will give a corporate presentation at the Zooming with LD Micro virtual conference on Thursday, April 15, 2021 at 11:00 AM ET followed by a live Q&A session with registered investors and other conference attendees. In addition, Mr. Eiswirth will be available for virtual one-on-one meetings the same day.

Registration link: https://us02web.zoom.us/webinar/register/WN_AnmlPmPwSHGD5rRTJtxp6w

About Alimera Sciences, Inc.

Alimera Sciences is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. Alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and affect millions of people in our aging populations. For more information, please visit www.alimerasciences.com.

For press inquiries:
Jules Abraham
for Alimera Sciences
917-885-7378
julesa@coreir.com
For investor inquiries:
Scott Gordon
for Alimera Sciences
scottg@coreir.com


Alimera Sciences, Inc.

NASDAQ:ALIM

ALIM Rankings

ALIM Latest News

ALIM Stock Data

181.15M
8.06M
8.75%
91.96%
0.21%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
ALPHARETTA

About ALIM

alimera, founded in june 2003, is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. alimera is presently focused on diseases affecting the back of the eye, or retina, because these diseases are not well treated with current therapies and will affect millions of people in aging populations. alimera's commitment to retina specialists and their patients is manifest in its product and in its development portfolio designed to treat early- and late-stage diseases. for more information, please visit www.alimerasciences.com. alimera's european operations are conducted from london by its subsidiary, alimera sciences limited.